Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.748 USD | +2.47% |
|
+1.77% | -30.09% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 109.1 | 70.72 | 48.84 | 35.86 | - | - |
Enterprise Value (EV) 1 | 109.1 | 70.72 | 48.84 | 35.86 | 35.86 | 35.86 |
P/E ratio | - | -3.37 x | -3.34 x | -2.67 x | -2.84 x | -37.4 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 26.4 x | 22.9 x | 15.1 x | 9.04 x | 4.5 x | 1.06 x |
EV / Revenue | 26.4 x | 22.9 x | 15.1 x | 9.04 x | 4.5 x | 1.06 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | -4.66 x | -3.76 x | -2.47 x | -3.03 x | -2.98 x |
FCF Yield | - | -21.5% | -26.6% | -40.5% | -33% | -33.6% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 35,780 | 45,623 | 45,642 | 47,939 | - | - |
Reference price 2 | 3.050 | 1.550 | 1.070 | 0.7480 | 0.7480 | 0.7480 |
Announcement Date | 4/1/22 | 3/29/23 | 4/3/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 4.138 | 3.085 | 3.229 | 3.966 | 7.966 | 33.87 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -9.724 | -16.74 | -15.58 | -13.55 | -13.33 | -0.875 |
Operating Margin | - | -234.99% | -542.59% | -482.38% | -341.67% | -167.35% | -2.58% |
Earnings before Tax (EBT) 1 | - | - | -16.98 | -14.65 | -13.14 | -13.31 | -1.075 |
Net income 1 | -4.528 | - | -16.98 | -14.65 | -13.48 | -13.34 | -1.075 |
Net margin | - | - | -550.34% | -453.76% | -339.94% | -167.5% | -3.17% |
EPS 2 | - | - | -0.4600 | -0.3200 | -0.2800 | -0.2633 | -0.0200 |
Free Cash Flow 1 | - | - | -15.18 | -13 | -14.52 | -11.83 | -12.04 |
FCF margin | - | - | -492.16% | -402.63% | -366.11% | -148.47% | -35.56% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/25/21 | 4/1/22 | 3/29/23 | 4/3/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 S1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 2.073 | 0.765 | 0.634 | 0.939 | 0.71 | 0.937 | 0.327 | 1.255 | 0.743 | 0.9255 | 0.7885 | 1.242 | 1 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | - | -4.281 | -4.101 | -3.932 | -3.957 | -4.081 | -4.123 | -3.415 | -3.65 | -3.558 | -3.592 | -3.554 | - |
Operating Margin | - | -559.61% | -646.85% | -418.74% | -557.32% | -435.54% | -1,260.86% | -272.11% | -491.25% | -384.39% | -455.61% | -286.08% | - |
Earnings before Tax (EBT) 1 | - | - | -4.058 | -3.952 | -3.768 | -3.889 | -4 | -2.995 | -3.609 | -3.59 | -3.67 | -3.47 | - |
Net income 1 | 3.847 | - | -4.058 | -3.952 | -3.768 | -3.889 | -4 | -2.995 | -3.609 | -3.537 | -3.572 | -3.534 | - |
Net margin | 185.58% | - | -640.06% | -420.87% | -530.7% | -415.05% | -1,223.24% | -238.65% | -485.73% | -382.17% | -453.01% | -284.43% | - |
EPS 2 | 0.1560 | - | -0.1100 | -0.1060 | -0.0800 | -0.0880 | -0.0870 | -0.0600 | -0.0800 | -0.0700 | -0.0700 | -0.0750 | -0.0700 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 9/23/21 | 8/15/22 | 12/5/22 | 3/29/23 | 5/22/23 | 8/14/23 | 11/15/23 | 4/3/24 | 5/28/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | -15.2 | -13 | -14.5 | -11.8 | -12 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | 0.89 | 0.48 | 0.25 | 0.25 | 0.25 |
Capex / Sales | - | - | 28.88% | 14.87% | 6.3% | 3.14% | 0.74% |
Announcement Date | 3/25/21 | 4/1/22 | 3/29/23 | 4/3/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.09% | 35.86M | |
+1.04% | 205B | |
+4.02% | 178B | |
+31.77% | 158B | |
+31.66% | 112B | |
+2.74% | 64.58B | |
+20.45% | 55.34B | |
-3.54% | 46.64B | |
-9.32% | 36.78B | |
-1.25% | 34.85B |
- Stock Market
- Equities
- ICCM Stock
- Financials IceCure Medical Ltd